27 related articles for article (PubMed ID: 16086877)
1. The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China.
Rui M; Wang Z; Fei Z; Wu Y; Wang Y; Sun L; Shang Y; Li H
Front Pharmacol; 2022; 13():862640. PubMed ID: 35370659
[No Abstract] [Full Text] [Related]
2. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations.
Yang JJ; Zhou Q; Yan HH; Zhang XC; Chen HJ; Tu HY; Wang Z; Xu CR; Su J; Wang BC; Jiang BY; Bai XY; Zhong WZ; Yang XN; Wu YL
Br J Cancer; 2017 Feb; 116(5):568-574. PubMed ID: 28103612
[TBL] [Abstract][Full Text] [Related]
3. Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients.
Li MJ; He Q; Li M; Luo F; Guan YS
Onco Targets Ther; 2016; 9():1291-302. PubMed ID: 27022285
[TBL] [Abstract][Full Text] [Related]
4. Clinical experiences with molecular targeted therapy in lung cancer in China.
Wang Y; Sun Y
Thorac Cancer; 2015 Jul; 6(4):379-84. PubMed ID: 26273390
[TBL] [Abstract][Full Text] [Related]
5. [A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China].
Li L; Zhong W; Liao M; Chen L; Han B; Guan Z; Yu S; Liu X; Wu Y; Jiang G; Xu J; Chen J; Tao M; Luo R; Li W; Xu N; Zhao X; Wang M
Zhongguo Fei Ai Za Zhi; 2012 Jun; 15(6):332-9. PubMed ID: 22681919
[TBL] [Abstract][Full Text] [Related]
6. Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib.
Wang F; Zhang Y; Zhao H; Chen L; Shi YX; Zhang L
Med Oncol; 2011 Mar; 28(1):331-5. PubMed ID: 20204544
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib.
Chen F; Luo X; Zhang J; Lu Y; Luo R
Med Oncol; 2010 Sep; 27(3):950-7. PubMed ID: 19830603
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer.
Cersosimo RJ
Am J Health Syst Pharm; 2004 May; 61(9):889-98. PubMed ID: 15156965
[TBL] [Abstract][Full Text] [Related]
9. Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature.
Yan DF; Yan SX; Yang JS; Wang YX; Sun XL; Liao XB; Liu JQ
BMC Cancer; 2010 Feb; 10():49. PubMed ID: 20170543
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial].
Guan ZZ; Zhang L; Li LY; Jiang GL; Liu XY; Chu DT; Zhao HY; Li W
Ai Zheng; 2005 Aug; 24(8):980-4. PubMed ID: 16086877
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of gefitinib on advanced non-small cell lung cancer in expanded access program (EAP)].
Zhang Y; Zhang L; Xu F; Wang ZQ; Zhao HY; Guan ZZ; Xu GC; Pan ZK
Ai Zheng; 2006 Dec; 25(12):1561-4. PubMed ID: 17166387
[TBL] [Abstract][Full Text] [Related]
12. [Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].
Tang CH; Liu XQ; Gao HJ; Li JJ; Guo WF; Li XY; Wang WX; Liu B; Qu LL; Wang WW
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):143-7. PubMed ID: 20403247
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)].
Huang H; Zhang Y; Zhao HY; Wang ZQ; Xu F; Xu GC; Zhang L; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):148-51. PubMed ID: 19538895
[TBL] [Abstract][Full Text] [Related]
14. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
15. [Gefitinib in the treatment of male patients with advanced non-small-cell lung cancer].
Wang B; Zhang XR; Chu DT
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):549-51. PubMed ID: 18069641
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
